Avoiding Antiplatelet Reversal in Non-Operative Intracranial Hemorrhages: Functional Outcomes of Guideline-Based Practice

Angelo d'Antonio-Bertagnolli  
*Thomas Jefferson University*, angelo.dantonio-bertagnolli@jefferson.edu

Lyena Birkenstock  
*Thomas Jefferson University*, lyena.birkenstock@jefferson.edu

Ariya Mobaraki  
*Thomas Jefferson University*, ariya.mobaraki@jefferson.edu

Christine Hammer, MD  
*Thomas Jefferson University*, christine.hammer@jefferson.edu

Syed O. Shah, MD  
*Thomas Jefferson University*, syed.shah@jefferson.edu

Follow this and additional works at: [https://jdc.jefferson.edu/si_ctr_2022_phase1](https://jdc.jefferson.edu/si_ctr_2022_phase1)

Let us know how access to this document benefits you

See next page for additional authors

**Recommended Citation**

d'Antonio-Bertagnolli, Angelo; Birkenstock, Lyena; Mobaraki, Ariya; Hammer, MD, Christine; Shah, MD, Syed O.; Jallo, MD, PhD, Jack; and Pendleton, MD, Courtney, "Avoiding Antiplatelet Reversal in Non-Operative Intracranial Hemorrhages: Functional Outcomes of Guideline-Based Practice" (2020). *Phase 1*. Paper 83.  
[https://jdc.jefferson.edu/si_ctr_2022_phase1/83](https://jdc.jefferson.edu/si_ctr_2022_phase1/83)

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Phase 1 by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.
Authors
Angelo d'Antonio-Bertagnolli; Lyena Birkenstock; Ariya Mobaraki; Christine Hammer, MD; Syed O. Shah, MD; Jack Jallo, MD, PhD; and Courtney Pendleton, MD

This abstract is available at Jefferson Digital Commons: https://jdc.jefferson.edu/si_ctr_2022_phase1/83
Avoiding Antiplatelet Reversal in Non-Operative Intracranial Hemorrhages: Functional Outcomes of Guideline-Based Practice

Angelo d’Antonio-Bertagnolli BS, Lyena Birkenstock BS, Ariva Mobarak BS, Christine Hammer MD, Syed O Shah MD, Jack Jallo MD PhD, Courtney Pendleton MD *

(*) indicates primary project advisor

(**) indicates another student who is declaring the same project as primary for SI

Introduction: Intracranial hemorrhage (ICH) is a common, life-threatening neurological pathology in aging patients, many of whom take antiplatelet medications with potential to worsen the hemorrhage. In the event of ICH, Thomas Jefferson University Hospital (TJUH) follows a protocol modeling the 2016 Neurocritical Care Society (NCS) joint guidelines for antiplatelet medication reversal. We analyzed pre- and post-NCS guideline data from TJUH for outcomes of non-operative ICH patients in order to tease out the potential benefits of this protocol.

Methods: This retrospective cohort study took place from January 2016 – Jan. 2018 at a tertiary care center: TJUH. Patients included were ≥18 y.o., on antiplatelet therapy who, had CTs available for evaluation of expansion, and did not undergo surgical management. The primary outcomes measured for comparison were both the admission and discharge Glasgow Coma Scores (GCS), admission and discharge modified Rankin Scores (mRS), time to death, hematoma expansion, and in-hospital mortality. T-tests, the Kolmogorov-Smirnov-test, and Chi-Square test for independence were used.
**Results:** For pre- and post-protocol groups, no significant difference existed for GCS or mRS, at admission and discharge. There were no significant findings for in-hospital mortality and hemorrhage expansion.

**Discussion:** TJUH established a protocol in line with the 2016 NCS joint guidelines for managing ICH in patients on antiplatelet therapies. This protocol recommends discontinuing antiplatelet therapy and not transfusing platelets in patients not receiving surgical management. We examined the protocol efficacy have found no significant differences in the pre- and post-protocol groups, indicating patient outcomes may be equivalent.